At variance with this model, we found that reexpression of PRKN in cancer does not cause mitophagy or other hallmarks of mitochondrial dysfunction (30) and potently activates, rather than inhibits, innate immunity through DAMP-regulated IFN signaling. Here, PRKN is linked to cancer.